Corcept Therapeutics (CORT) Stock Price, News & Analysis

Company Overview

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. Beyond Korlym, Corcept is advancing a proprietary pipeline of selective glucocorticoid receptor modulators, most notably relacorilant. Relacorilant is under investigation in multiple clinical trials for indications including endogenous Cushing’s syndrome, platinum-resistant ovarian cancer and psychotic major depression, reflecting Corcept’s commitment to expanding therapeutic options where cortisol dysregulation plays a key role.

Founded in 1998 and headquartered in Redwood City, California, Corcept went public in 2012 to support its transition from research to commercialization. Since then, the company has built a specialized commercial organization in the United States and is pursuing regulatory filings and partnerships in Europe and other regions. Corcept collaborates with academic institutions, clinical research centers and regulatory authorities to advance its programs from proof of concept through pivotal trials.

Corcept is led by President and CEO Joseph K. Belanoff, M.D., who co-founded the company and has guided its scientific and strategic direction for more than two decades. Under his leadership, Corcept has established a multidisciplinary team of researchers, clinicians and commercial experts. The company continues to explore novel approaches to glucocorticoid receptor modulation with the goal of delivering transformative therapies for patients affected by debilitating cortisol-related disorders.

Key Stats

• Today's Range: $114.39 to $117.00
• 50-Day Range: $73.33 to $118.32
• 52-Week Range: $28.66 to $122.21
• Volume: 154,057 shs
• Average Volume: 1.55 million shs
• Market Capitalization: $12.62 billion
• P/E Ratio: 278.08
• Dividend Yield: N/A
• Price Target: $119.17
• Consensus Rating: Moderate Buy

Corcept Therapeutics Stock Analysis - MarketRank™

Corcept Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 459th out of 915 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Corcept Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 1 strong buy rating, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Corcept Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Corcept Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 107.96%

Earnings Growth

Earnings for Corcept Therapeutics are expected to grow by 107.96% in the coming year, from $1.13 to $2.35 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corcept Therapeutics is 275.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corcept Therapeutics is 275.29, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.47.

Price to Book Value per Share Ratio

Corcept Therapeutics has a P/B Ratio of 18.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.46% of the float of Corcept Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Corcept Therapeutics has a short interest ratio ("days to cover") of 6.38.

Change versus previous month

Short interest in Corcept Therapeutics has recently increased by 3.99%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corcept Therapeutics does not currently pay a dividend.

Dividend Growth

Corcept Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.04

News Sentiment

Corcept Therapeutics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Corcept Therapeutics this week, compared to 12 articles on an average week.

Search Interest

16 people have searched for CORT on MarketBeat in the last 30 days.

MarketBeat Follows

7 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,118,563.00 in company stock.

Percentage Held by Insiders

20.70% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 8/17/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CORT
• CIK: 1088856
• Web: www.corcept.com
• Phone: (650) 327-3270
• Fax: 650-327-3218
• Employees: 300
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Corcept Therapeutics: $119.17
• High Price Target: $165.00
• Low Price Target: $50.00
• Potential Upside/Downside: +2.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.42
• Trailing P/E Ratio: 276.20
• Forward P/E Ratio: 102.65
• P/E Growth: N/A
• Net Income: $99.65 million
• Net Margins: 6.52%
• Pretax Margin: 3.17%
• Return on Equity: 8.26%
• Return on Assets: 6.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.86
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: $830.81 million
• Price / Sales: 15.09
• Cash Flow: $0.91 per share
• Price / Cash Flow: 126.80
• Book Value: $6.16 per share
• Price / Book: 18.83

Miscellaneous

• Outstanding Shares: 108,098,000
• Free Float: 85,722,000
• Market Cap: $12.54 billion
• Optionable: Optionable
• Beta: 0.45